These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21282280)

  • 21. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.
    Aguiar P; Monteiro L; Feres A; Gomes I; Melo A
    Curr Alzheimer Res; 2014; 11(6):532-7. PubMed ID: 24938502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
    Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
    Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
    Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
    Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
    Cummings J; Winblad B
    Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
    Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
    Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
    Potki SG; Anand R; Hartman R; Veach J; Grossberg G
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):713-20. PubMed ID: 12188104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
    Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
    Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
    Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
    Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
    Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
    Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
    Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
    J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
    Feldman HH; Lane R;
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.